Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Atea Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 128 | 2 | 126 | 0 |
| Shares | 57.5M | 234 | 57.4M | −64.0K (−0.1%) |
| Value | $408.7M | $1.55K | $326.8M | −$81.9M (−20.0%) |
2 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 360,000 | $2.05M | 1.35% |
| First Trust Advisors LP | 199,279 | $1.13M | 0.00% |
| Candriam Luxembourg S.C.A. | 129,329 | $736.0K | 0.01% |
| PDT Partners, LLC | 68,754 | $391.0K | 0.06% |
| Virtu Financial LLC | 30,693 | $175.0K | 0.02% |
| D. E. Shaw & Co., Inc. | 29,157 | $166.0K | 0.00% |
| Virginia Retirement Systems Et Al | 27,100 | $154.2K | 0.00% |
| Ameriprise Financial Inc | 22,965 | $131.0K | 0.00% |
| Janus Henderson Group PLC | 18,139 | $104.0K | 0.00% |
| Gladius Capital Management LP | 4,849 | $28.0K | 0.00% |
| Denali Advisors LLC | 4,400 | $25.0K | 0.01% |
| China Universal Asset Management Co., Ltd. | 780 | $4.00K | 0.00% |
| US Bancorp | 364 | $2.00K | 0.00% |
| CWM, LLC | 24 | $0 | 0.00% |
| Wipfli Financial Advisors LLC, | 39 | $0 | 0.00% |
Sold out (15)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Voloridge Investment Management, LLC | 265,365 | $1.88M |
| Privium Fund Management (UK) Ltd | 61,284 | $435.0K |
| Qube Research & Technologies Ltd | 60,067 | $426.0K |
| Atom Investors LP | 30,911 | $219.0K |
| Cubist Systematic Strategies, LLC | 26,656 | $189.0K |
| Wexford Capital LP | 25,000 | $178.0K |
| Gsa Capital Partners LLP | 25,080 | $178.0K |
| Panagora Asset Management Inc | 23,032 | $164.0K |
| Two Sigma Advisers, LP | 21,800 | $155.0K |
| Blair William & Co | 14,439 | $103.0K |
| Arrowstreet Capital, Limited Partnership | 10,878 | $77.0K |
| Prelude Capital Management, LLC | 10,196 | $72.0K |
| Geneos Wealth Management Inc. | 1,000 | $7.00K |
| South State Corp. | 565 | $4.00K |
| Captrust Financial Advisors | 502 | $4.00K |
Not filed for Q3 2022 yet (2)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Private Capital Group, LLC | 156 | $1.00K |
| Exane Derivatives | 78 | $554 |